|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:class
|
immunomodulator
anti-TNF agent
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
short-term treatment
long-term treatment
|
|
gptkbp:contraindication
|
active infections
severe allergic reactions
congestive heart failure
|
|
gptkbp:dosage_form
|
auto-injector
pre-filled syringe
|
|
gptkbp:effective_date
|
gptkb:1998
FDA approved
EMA approved
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:formulation
|
solution for injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Enbrel
|
|
gptkbp:ingredients
|
gptkb:etanercept
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
regular blood tests recommended
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
gptkb:Amgen
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
TNF inhibitor
|
|
gptkbp:patient_population
|
gptkb:children
adults
|
|
gptkbp:previous_name
|
gptkb:etanercept
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_guidance_on
|
recommended for certain conditions
|
|
gptkbp:research_areas
|
autoimmune diseases
chronic inflammatory diseases
|
|
gptkbp:route_of_administration
|
subcutaneous injection
|
|
gptkbp:safety_measures
|
post-marketing surveillance conducted
|
|
gptkbp:service_frequency
|
once a week
once every two weeks
|
|
gptkbp:side_effect
|
headache
nausea
rash
infections
injection site reactions
blood disorders
nervous system disorders
liver problems
lymphoma risk
serious infections risk
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:trade
|
gptkb:Enbrel
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:type_of_insurance
|
varies by plan
|
|
gptkbp:used_for
|
gptkb:rheumatoid_arthritis
gptkb:ankylosing_spondylitis
gptkb:psoriatic_arthritis
plaque psoriasis
|
|
gptkbp:bfsParent
|
gptkb:Amgen
|
|
gptkbp:bfsLayer
|
4
|